Inovio Pharmaceuticals Inc (INO)

[biovalidator]

Email from Inovio at 1:55

Thank you for listening to Dr. Kim’s corporate presentation at Biotech Showcase 2014. 2013 was a dynamic year for Inovio. We reported and published best-in-class T-cell responses from multiple clinical studies as well as finalized a validating license deal with Roche for two of Inovio’s pre-clinical cancer products.


2014 will be just as dynamic and potentially transformative. We expect to initiate phase I and phase I/IIa clinical trials targeting cervical cancer, head and neck cancer, prostate cancer, breast and lung cancer, HIV and malaria. We have the prospect of additional partnerships. Importantly, we will report Inovio’s efficacy data from our phase II clinical trial targeting HPV-caused cervical dysplasias.


We appreciate your interest in Inovio. Please let us know if you have questions.

Best regards,

Bernie Hertel
Senior Director, Communications & IR
[e-mail]
858 336 5579